We are studying how responses to the rotavirus vaccine are influenced by infant nutrition and other exposures in different areas of the world. The information we get from this study may help us to understand how to best protect infants from rotavirus and other infections.
Learn about the development of bacterial infections in shunted hydrocephalus.
We are studying the role of gut microbiome diversity on the mucosal and systemic responses to Ty21a vaccine. This is to determine if a given microbiota composition is associated with specific immune responses and to evaluate the impact of an oral typhoid vaccination on the human gut microbiota.
To find out how SARS-CoV-2 is spread throughout a household.
The purpose of this study is to understand the impact of the COVID-19 pandemic on vulnerable families in Los Angeles, including those caring for a child with special health care needs. Information from this research will be used to understand what the key resource and service needs of families are at this time as well as identify interventions that can be developed or adapted to address these needs.
The effect of flu immunization on the level of immunity against the flu in breastmilk, and how this may help protect a breastfeeding infant.
To test a new experimental drug Temisirolimus - Temsirolimus (also known as Torisel®) is approved for kidney cell cancer treatment in adults - in combination with approved chemotherapy drugs - in the hopes of finding a drug combination that may be effective against leukemia and non-hodgkin’s lymphoma that has come back after initial treatment. To find the highest dose that can be given without casing severe side effects.
Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.
The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.
This study aims to evaluate the side effects (good and bad) of giving Vincristine Suflate Liposome Infection (also known as Marqibo®) - a drug approved for leukemia treatment in adults but that is experimental in children - with other standard chemotherapy drugs and to measure how effective the combination is at treating children and young adults with leukemia that has come back after initial treatment.
